INDIVIDUALIZED THERAPEUTIC ANTICANCER VACCINE

Abstract

The present invention relates to an individualized therapeutic anticancer vaccine, methods of treatment of cancer wherein such an anticancer vaccine is used as well as methods for producing the vaccine.

Description

Claims

1. An individualized therapeutic anticancer vaccine comprising an immunologically effective amount of: (i) a polynucleotide comprising a nucleotide sequence encoding a targeting unit, a dimerization unit and an antigenic unit, wherein said antigenic unit comprises at least one patient-present shared antigen sequence or one or more parts thereof and wherein said antigenic unit further comprises one or more patient-specific antigen sequences or one or more parts thereof; or(ii) a polypeptide encoded by the polynucleotide as defined in (i); or(iii) a dimeric protein consisting of two polypeptides encoded by the polynucleotide as defined in (i); and a pharmaceutically acceptable carrier.

2. (canceled)

3. The vaccine according to claim 1, wherein said at least one patient-present shared antigen sequence is a sequence of a shared antigen selected from the group consisting of overexpressed cellular proteins, aberrantly expressed cellular proteins, cancer testis antigens, viral antigens, differentiation antigens, mutated oncogenes, mutated tumor suppressor genes, oncofetal antigens, shared fusion antigens, shared intron retention antigens, dark matter antigens, shared antigens caused by spliceosome mutations and shared antigens caused by frameshift mutations-, and/or wherein said at least one patient-present shared antigen sequence is a sequence of a shared antigen that is a human cellular protein, and/or wherein said at least one patient-present shared antigen sequence or one or more parts thereof are known to be immunogenic or are predicted to bind to the patient’s HLA class I and/or HLA class II alleles.

4-6. (canceled)

7. The vaccine according to claim 1, wherein the antigenic unit comprises sequences of several patient-present shared antigens or one or more parts thereof.

8. (canceled)

9. The vaccine according to claim 7, wherein the antigenic unit comprises several epitopes of several patient-present shared antigens, which epitopes are known to be immunogenic or are predicted to bind to the patient’s HLA class I and/or HLA class II alleles.

10. The vaccine according to claim 1, wherein the antigenic unit comprises one or more patient-present shared antigen sequences in full length, and/or wherein the antigenic unit comprises 1 to 30 parts of at least one patient-present shared antigen sequence, wherein the parts include multiple epitopes that are known to be immunogenic or are predicted to bind to the patient’s HLA class I and/or HLA class II alleles.

11-12. (canceled)

13. The vaccine according to claim 1, wherein the antigenic unit comprises 1 to 50 patient-present shared antigen sequences in the form of epitopes, wherein the epitopes are known to be immunogenic or predicted to bind to the patient’s HLA class I and/or HLA class II alleles.

14. (canceled)

15. The vaccine according to claim 13, wherein the epitopes have a length of from 7 to 30 amino acids.

16. The vaccine according to claim 1, wherein the antigenic unit comprises several patient-specific antigen sequences or one or more parts thereof, and/or wherein the antigenic unit comprises one or more patient-specific epitopes.

17-18. (canceled)

19. The vaccine according to claim 16, wherein antigenic unit comprises at least 5 patient-specific epitopes.

20-21. (canceled)

22. The vaccine according to claim 1, wherein the dimerization unit comprises a hinge region, and further comprises another domain that facilitates dimerization.

23-25. (canceled)

26. The vaccine according to claim 1, wherein the dimerization unit comprises hinge exons h1 and h4 connected through a linker to a CH3 domain of human IgG3.

27-28. (canceled)

29. The vaccine according to claim 1, wherein the targeting unit comprises or consists of soluble CD40 ligand, RANTES, MIP-1α, XCL1, XCL2, flagellin, anti-HLA-DP, anti-HLA-DR, anti-pan HLA class II or an antibody variable domain with specificity for anti-CD40, anti-TLR-2, anti-TLR-4 or anti-TLR-5 .

30. The vaccine according to claim 1, wherein said vaccine comprises a polynucleotide which is an RNA or DNA and further comprises a nucleotide sequence encoding a signal peptide.

31. The vaccine according to claim 30, wherein the polynucleotide is a DNA.

32. (canceled)

33. The vaccine according to claim 1, wherein the pharmaceutically acceptable carrier is selected from the group consisting of saline, buffered saline, PBS, dextrose, water, glycerol, ethanol, sterile isotonic aqueous buffers, and combinations thereof.

34. A method for preparing the individualized therapeutic anticancer vaccine of claim 1, said method comprises the steps of: a) identifying at least one patient-present shared antigen in the tumor tissue or body fluid of a patientb) determining the patient’s HLA class I and/or class II allelesc) predicting the immunogenicity of the identified at least one antigen or one or more parts thereof by their predicted binding to the patient’s HLA class I and/or II allelesd) selecting at least one antigen or one or more parts thereof based on their immunogenicity predicted in step c);e) preparing a polynucleotide sequence comprising an antigenic unit comprising a nucleotide sequence encoding the at least one antigen or one or more parts thereof selected in step d);f) cloning the polynucleotide sequence into an expression vector comprising nucleotide sequences encoding a targeting unit and a dimerization unit; andg) mixing the expression vector obtained in step f with a pharmaceutically acceptable carrier, and wherein said method further comprises: in step a) identifying one or more patient-specific antigens in the tumor tissue of the patient in step c) predicting the immunogenicity of the identified one or more patient-specific antigens or one or more parts thereof by their predicted binding to the patient’s HLA class I and/or II allelesin step d) selecting one or more patient-specific antigens or one or more parts thereof based on their immunogenicity predicted in step c);and wherein the polynucleotide sequence of step e) further comprises nucleotide sequences encoding the one or more patient-specific antigens or one or more parts thereof selected in step d).

35. (canceled)

36. A polynucleotide as defined in claim 1.

37. The polynucleotide according to claim 36 wherein the polynucleotide is comprised in a vector.

38-42. (canceled)

43. A method of treating a patient having cancer, the method comprising administering to the patient the vaccine according to claim 1, which has been prepared specifically for the patient.

44. (canceled)

45. The vaccine according to claim 1, wherein the targeting unit comprises or consists of MIP-1α.